Sepsis/Systemic Inflammatory Response Syndrome (SIRS) is the body’s response to infectious (ie bacterial infection) or noninfectious (ie trauma, organ transplantation, burn) insult, resulting in multiple organ failure. Sepsis is the leading cause of death from infection worldwide.
Overwhelming activation of vascular endothelium and leukocytes are the key events contributing to sepsis/SIRS-induced injury and dysfunction of the affected organs.
My research focuses on the mechanisms of sepsis/SIRS-induced activation of neutrophilic leukocytes and organ-specific vascular endothelial cells with respect to generation of the oxidative/nitrosative/proteolytic stresses, production of inflammatory cytokines, up-regulation of the pro-adhesive phenotype, and subsequent changes in vascular permeability and recruitment of the inflammatory cells. Carbon monoxide releasing molecules (CORMs) are used as new treatment to counteract sepsis/SIRS-induced inflammatory response.
|1979-1984||D.V.M. (Lithuanian Academy of Veterinary Sciences|
|1984-1987||Ph.D. (Institute of Biochemistry, Lithuanian Academy of Sciences)|
|1991-1995||Postdoctoral Fellow (LSU Medical Center, Shreveport, LA)|
|1995-1997||Postdoctoral Fellow (Victoria Hospital Research Institute, London, ON, Canada)
Ongoing research partnership with:
Dr. Douglas D. Fraser - Traumatic Brain Injury, Sepsis, Blood-Brain-Barrier dysfunction, Diagnostic Biomarkers, COVID-19 Inflammatory Blood Biomarkers
Dr. Abdel Lawendy - Carbon monoxide releasing molecules (CORMs) in treatment of Limb Compartment Syndrome
Drs. Partick Luke and Alp Sener - Carbon monoxide releasing molecules (CORMs) in kidney transplantation
Dr. Kevin Shoemaker - Cerebrovascular outcomes in ischemic heart disease patients undergoing cardiac rehabilitation